Results 101 to 110 of about 8,158 (292)
Enteroinsular axis: physiology and pathophysiology : Metabolic and pleiotropic effects of incretins [PDF]
, 2021 A better understanding of GLP-1 and GIP biology, physiology and pathophysiology are currently within the focus of many labs across the world, since they are in the basement of the development of new therapies for treating type 2 Diabetes and obesity ...
Gagliardino, Juan José +1 more
core
Diabetes, Metabolic Syndrome and Obesity, 2019 Marie Bastin, Fabrizio Andreelli Diabetology-Metabolism Department, Sorbonne Université, ICAN, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, F-75013, FranceCorrespondence: Fabrizio ...
Bastin M, Andreelli F
doaj
British Journal of Pharmacology, EarlyView.Abstract Gastric inhibitory polypeptide (GIP)/Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are increasingly prescribed for the management of obesity and type 2 diabetes, yet research pertinent to their effects on muscle health is limited. Considering the central role of muscle strength as a sarcopenia component, this article summarizes emerging ...
Konstantinos Prokopidis
wiley +1 more source
Prevalence of hypoglycaemia in a random population after Roux-en-Y gastric bypass after a meal test
Endocrine Connections, 2019 Objective: Roux-en-Y gastric bypass (RYGB) is an effective way to induce sustainable weight loss and can be complicated by postprandial hyperinsulinaemic hypoglycaemia (PHH).
Marloes Emous +8 more
doaj +1 more source
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
British Journal of Pharmacology, EarlyView.Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley +1 more source
Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity
Periodontology 2000, EarlyView., 2023 Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti +2 more
wiley +1 more source
The Journal of PhysiologyAbstract The incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) play critical roles in co‐ordinating postprandial metabolism, including modulation of insulin secretion and food intake.
Constanza Alcaino +2 more
openaire +3 more sources
Amylin analogues as a novel perspective in anti‐obesity therapy
British Journal of Pharmacology, EarlyView.Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley +1 more source
Indian Journal of Endocrinology and Metabolism, 2011 The treatment of type 2 diabetes mellitus (T2DM) has included the use of metformin and sulfonylurea (SU) as first-line anti-diabetic therapies world over since years.
Vishal Gupta, Sanjay Kalra
doaj +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus +7 more
wiley +1 more source